Drug intelligence / Profile preview

ALS-3

Development stage: Preclinical
Lead developer: Bristol Myers Squibb

Overview

ALS-3 is a preclinical drug candidate being developed by insitro for the treatment of Amyotrophic Lateral Sclerosis (ALS). It was identified through insitro's proprietary platform, which utilizes machine learning and high-content cellular imaging of human-derived models to discover novel therapeutic targets. The program aims to identify disease-modifying treatments for ALS, a progressive neurodegenerative disease characterized by the loss of motor neurons. While the specific target and modality for ALS-3 have not been publicly disclosed, it represents one of several assets in insitro's neuroscience pipeline.

Targets

Als3 (Agglutinin-like sequence protein 3)

Beyond the preview

Go deeper on ALS-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALS-3.

Explore the full profile